Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Andreas von Planta 
        • Charles Sawyers 
        • William Winters 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Marie-France Tschudin 
        • Lutz Hegemann 
        • Kees Roks 
        • Richard Saynor 
        • Michael Willi 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Innovative Medicines 
      • Sandoz 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      Male scientist in lab About Novartis
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • COVID-19: Patients and Caregivers 
      • Stories: Patients Perspectives 
      Couple holding hands Patients & Caregivers
    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
        • Abstract summaries for EADV 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor Healthcare Professionals
    • Research & Development 
      • Novartis Institutes for BioMedical Research 
        • Collaborations 
        • NIBR Global Scholars Program 
      • Technology Platforms 
        • Radioligand Therapy 
        • Gene Therapy 
        • Cell Therapy 
      • Research Disease Areas 
        • Immuno-oncology research at Novartis 
        • Oncology research at Novartis 
        • Cardiovascular and metabolic disease research at Novartis 
        • Autoimmunity, transplantation and inflammatory disease research at Novartis 
        • Ophthalmology research at Novartis 
        • Neuroscience Research at Novartis 
        • Musculoskeletal Disease Research at Novartis 
        • DAx: exploratory disease research at Novartis 
      • Research Locations 
        • Novartis Institute for Tropical Diseases 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research & Development Approach 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments Research & Development
    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Anti-Microbial Resistance (AMR) 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda Environmental, Social and Governance
    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube Investors
    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens News
    • Careers 
      • Career Search 
      • Our Teams 
        • Careers in Commercial 
        • Careers in Communications and Engagement 
        • Careers in Consulting 
        • Careers in Digital 
        • Careers in Health, Safety & Environment 
        • Careers in Information Technology (IT) 
        • Careers in Medical & Development 
        • Careers in People & Organization 
        • Careers in Procurement 
        • Careers in Research 
        • Careers in Strategy 
        • Careers in Manufacturing and Supply 
        • Ethics, Risk & Compliance (ERC) 
        • Careers in Legal 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Talent 
        • US NIBR Internship Programs 
      • International Careers 
      • Personal Growth 
      • Well-being 
      A female Novartis researcher Careers
    • Clinical Trials 
      doctor taking the blood pressure of her patient Clinical Trials
    • Partnering 
      Business people working in a dark room Partnering
    • Supplier Portal 
    • Report side effects 
    • Contacts 
      Office Cubicle Contacts
    Visitors enjoying the visit of the Novartis Pavillon Home
  1. Home
  2. Investors
  3. Novartis Financial Data
  4. Expected Currency Impact

Expected Currency Impact

Our expected currency impact, if currencies stay at mid-November levels in 2022 can be found below.

Download the presentation (PDF 0.3 MB)

AddToAny buttons

ShareTweetShareWhatsappLinkedinEmail

Printable Links Block (Content)

  • Print
  • PDF

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2022 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience